ACADIA Pharmaceuticals, Inc. (ACAD)
18.74
+0.60
(+3.31%)
USD |
NASDAQ |
Nov 13, 16:00
18.75
+0.01
(+0.05%)
After-Hours: 19:59
ACADIA Pharmaceuticals Enterprise Value : 2.230B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 2.230B |
| November 11, 2026 | 2.270B |
| November 10, 2026 | 2.254B |
| November 09, 2026 | 1.946B |
| November 06, 2026 | 2.764B |
| November 05, 2026 | 2.765B |
| November 04, 2026 | 2.805B |
| November 03, 2026 | 2.650B |
| November 02, 2026 | 2.632B |
| October 30, 2026 | 2.653B |
| October 29, 2026 | 2.683B |
| October 28, 2026 | 2.606B |
| October 27, 2026 | 2.581B |
| October 26, 2026 | 2.506B |
| October 23, 2026 | 2.505B |
| October 22, 2026 | 2.605B |
| October 21, 2026 | 2.584B |
| October 20, 2026 | 2.627B |
| October 19, 2026 | 2.517B |
| October 16, 2026 | 2.399B |
| October 15, 2026 | 2.501B |
| October 14, 2026 | 2.422B |
| October 13, 2026 | 2.313B |
| October 12, 2026 | 2.449B |
| October 09, 2026 | 2.513B |
| Date | Value |
|---|---|
| October 08, 2026 | 2.479B |
| October 07, 2026 | 2.491B |
| October 06, 2026 | 2.506B |
| October 05, 2026 | 2.570B |
| October 02, 2026 | 2.543B |
| October 01, 2026 | 2.532B |
| September 30, 2026 | 2.577B |
| September 29, 2026 | 2.598B |
| September 28, 2026 | 2.651B |
| September 25, 2026 | 2.677B |
| September 24, 2026 | 2.935B |
| September 23, 2026 | 3.495B |
| September 22, 2026 | 3.663B |
| September 21, 2026 | 3.661B |
| September 18, 2026 | 3.815B |
| September 17, 2026 | 3.842B |
| September 16, 2026 | 3.858B |
| September 15, 2026 | 3.724B |
| September 14, 2026 | 3.854B |
| September 11, 2026 | 3.908B |
| September 10, 2026 | 3.892B |
| September 09, 2026 | 3.882B |
| September 08, 2026 | 3.865B |
| September 04, 2026 | 3.941B |
| September 03, 2026 | 3.913B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ionis Pharmaceuticals, Inc. | 4.834B |
| Arcturus Therapeutics Holdings, Inc. | 77.26M |
| ADMA Biologics, Inc. | 3.028B |
| Immunic, Inc. | -48.24M |
| Viking Therapeutics, Inc. | 2.812B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 53.52M |
| Revenue (Quarterly) | 342.29M |
| Total Expenses (Quarterly) | 288.77M |
| EPS Diluted (Quarterly) | 0.305 |
| Gross Profit Margin (Quarterly) | 89.75% |
| Profit Margin (Quarterly) | 15.64% |
| Earnings Yield | 11.23% |
| Operating Earnings Yield | 3.77% |
| Normalized Earnings Yield | 11.23 |